(Q50927443)

25 March 2018

title

Even though T-cell-directed trials have been of limited success, is there reason for optimism? (English)

1 reference

25 March 2018

author name string

Gabriel S Panayi

series ordinal

1

1 reference

25 March 2018

publication date

1 February 2006

1 reference

25 March 2018

Nature Clinical Practice Rheumatology

published in

1 reference

25 March 2018

volume

2

1 reference

25 March 2018

issue

2

1 reference

25 March 2018

page(s)

58-59

1 reference

25 March 2018

Control of rheumatoid arthritis by oral tolerance

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0094

Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0094

Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0094

7 January 2021

Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0094

7 January 2021

T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0094

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0094

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0094

1 reference

25 March 2018

PubMed ID

16932654

1 reference

25 March 2018